KPV: Dosage, Benefits & Side Effects

By Peptide Assistant Editorial Team · · · 14 sources cited

Overview

KPV is a tripeptide (Lys-Pro-Val) derived from the C-terminal end of alpha-melanocyte-stimulating hormone (α-MSH), one of the body's most potent endogenous anti-inflammatory molecules. KPV retains the anti-inflammatory activity of the full α-MSH molecule but lacks its pigment-inducing effect. It has shown anti-inflammatory effects in mouse and rat models of colitis and in cell studies of gut, skin, and airway inflammation, but it has not been tested in human trials. KPV is emerging as a cornerstone peptide for gut health protocols and chronic inflammation management.

Mechanism of Action

Unlike full α-MSH, KPV does not appear to work mainly through melanocortin receptors: it did not raise cAMP in macrophages or keratinocytes, and it stayed effective in mice lacking a functional MC1R. Instead, studies show it enters cells and inhibits the NF-κB pathway — the master transcription factor governing inflammatory gene expression. In human airway epithelial cells, KPV stabilized IκBα (the inhibitory protein that keeps NF-κB sequestered in the cytoplasm) and blocked nuclear import of the NF-κB p65 subunit. In cell and animal studies this reduced production of pro-inflammatory cytokines including TNF-α, IL-1β, IL-6, and IL-8. Beyond NF-κB inhibition, KPV modulates several additional inflammatory cascades. It inhibits MAP kinase inflammatory signaling in intestinal epithelial and immune cells, and it reduced nitric oxide production by activated mouse microglial cells. It stabilizes mast cells, reducing histamine release and allergic-type inflammatory responses. In intestinal epithelial cells, KPV has been shown to directly enter cells through the PepT1 transporter (a peptide/proton cotransporter highly expressed in intestinal brush border), achieving intracellular concentrations that directly suppress inflammatory signaling within colonocytes. This PepT1-mediated uptake is particularly significant for IBD applications — it means oral or topical KPV can be directly absorbed by the inflamed intestinal epithelium, creating a targeted anti-inflammatory effect at the site of disease. KPV also reduces the expression of adhesion molecules (ICAM-1, VCAM-1) on endothelial cells, decreasing immune cell infiltration into inflamed tissues. In skin, it reduces keratinocyte and fibroblast production of inflammatory mediators while promoting wound healing through enhanced cell migration and proliferation. KPV has been proposed as an anti-inflammatory that would avoid the immunosuppression associated with corticosteroids or TNF-α inhibitors. In one laboratory study α-MSH peptides did not reduce the killing of microbes by human neutrophils, but whether KPV spares immune defense in people has not been tested.

KPV Benefits: What the Research Shows

  • Dalmasso et al. (2008) demonstrated in Gastroenterology that KPV is transported into intestinal epithelial and immune cells via PepT1 and inhibits NF-κB activation inside the cell — a mechanism distinct from melanocortin receptor signaling
  • Studies in murine colitis models (DSS-induced and T-cell transfer) showed KPV led to earlier recovery, regained body weight, and reduced inflammatory infiltrates and myeloperoxidase activity in the colon (Kannengiesser et al., Inflammatory Bowel Diseases, 2008); oral KPV in drinking water also reduced DSS and TNBS colitis in mice (Dalmasso et al., 2008)
  • Research by Brzoska et al. (2008) in Endocrine Reviews comprehensively reviewed α-MSH and its fragments (including KPV), documenting anti-inflammatory effects in animal models of fever, contact dermatitis, and gut, airway, eye, and joint inflammation
  • KPV (α-MSH 11-13) reduced IL-1 and TNF-α production in a concentration-dependent way in LPS-stimulated whole blood taken from HIV-infected patients (Peptides, 1998)
  • KPV has been proposed as a future candidate for treating skin wounds and ulcers because it keeps α-MSH's anti-inflammatory effects without its pigment-inducing activity (Böhm and Luger, Experimental Dermatology, 2019)
  • In rats with TNBS-induced colitis, KPV given rectally in a stabilizing hydrogel reduced disease activity scores, colon shortening, and colonic myeloperoxidase; plain KPV solution was reported to be very unstable when given rectally (Sun et al., 2021)
  • Studies on skin cells showed KPV inhibited TNF-α-stimulated NF-κB activation in human keratinocytes (Journal of Investigative Dermatology, 2002); the animal contact dermatitis studies were done with full α-MSH
  • KPV showed antimicrobial effects against Staphylococcus aureus and Candida albicans in laboratory cultures, including at physiological (picomolar) concentrations (Cutuli et al., Journal of Leukocyte Biology, 2000); a 2009 letter in the same journal reported being unable to reproduce the anti-Candida effect

KPV Dosage

  • Oral/sublingual for gut inflammation: 200–500 mcg once or twice daily, taken on an empty stomach for maximum intestinal absorption
  • Subcutaneous injection for systemic inflammation: 200–500 mcg once daily
  • Topical for skin inflammation: 0.01–0.1% KPV in a suitable vehicle (cream or serum), applied 1–2 times daily to affected areas
  • Gut-focused protocol: 500 mcg oral twice daily (morning and evening, fasted) for 8–12 weeks
  • Cycle: 8–12 weeks on, 4 weeks off, or continuous use at lower doses under practitioner guidance
  • BPC-157 + KPV gut protocol: combine 500 mcg KPV oral with 250 mcg BPC-157 oral twice daily for comprehensive gut healing
  • Can be compounded into capsules or enteric-coated formulations for targeted lower GI delivery
  • Rectal administration (suppository or enema) for distal colitis: 500 mcg daily
Peptide calculator: get your dose in syringe units →

Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.

KPV Side Effects & Safety

Known Side Effects

  • Side effects of KPV have not been studied in humans (the FDA has identified no human exposure data for it); the effects listed below come from user reports
  • Mild injection site reactions with subcutaneous route (redness, minor irritation)
  • Skin tanning is not expected: unlike full α-MSH and the Melanotan peptides, KPV lacks pigment-inducing activity in published research
  • Occasional mild GI changes (loose stools, gas) during first few days of oral use as gut inflammation modulates
  • Rare: mild headache during first 2–3 days
  • No human studies of KPV have been published, so adverse effects in people are undocumented

Safety Profile

KPV's safety in humans is unknown. It is a tripeptide derived from α-MSH — a hormone the body naturally produces — but the FDA states that it has not identified any human exposure data for KPV by any route and lacks information on whether it would cause harm if administered to humans, and it lists KPV among bulk drug substances that may present significant safety risks in compounding. Animal studies have focused on efficacy; no formal toxicity studies were found. Its mechanism of action (NF-κB modulation rather than broad immunosuppression) has been proposed to spare normal immune defense, but it has not been compared with corticosteroids, JAK inhibitors, or anti-TNF biologics in any human study. Theoretical considerations: those with melanoma should exercise caution because it derives from α-MSH (though studies indicate KPV lacks α-MSH's pigmentary action and is unlikely to act through melanocortin receptors). Not recommended during pregnancy or breastfeeding due to insufficient data. No drug interaction, combination, or long-term safety studies exist; periodic cycling is commonly recommended.

What to Expect

This timeline comes from user reports; KPV has not been studied in humans. Week 1: Subtle improvements in gut comfort — reduced bloating, less abdominal discomfort if IBD/IBS symptoms are present. Some users report a general sense of reduced inflammation (less joint stiffness, improved energy). Mild GI adjustment possible. Weeks 2–3: Gut function continues to improve — more regular bowel movements, reduced urgency and frequency in those with inflammatory bowel conditions. Systemic inflammation markers begin to decrease. Skin conditions (eczema, psoriasis) may show early improvement. Weeks 4–6: Significant improvement in inflammatory symptoms. Gut healing is well-established. Skin inflammation substantially reduced. Energy and well-being improved as chronic inflammatory burden decreases. Weeks 7–12: Maximum benefits achieved. Chronic inflammatory conditions show substantial improvement. Some users track zonulin or calprotectin levels, but no human study has measured these with KPV. Benefits often persist for weeks to months after discontinuation, suggesting genuine tissue healing rather than mere symptom suppression.

Common Stacks

Storage & Handling

Store lyophilized KPV at 2–8°C for up to 12 months or -20°C for up to 24 months. As a small tripeptide, KPV is relatively stable compared to larger peptides. Reconstitute with bacteriostatic water for injection use; for oral use, some practitioners dissolve in distilled water. Once reconstituted, refrigerate and use within 4 weeks. Protect from light. Solution should be clear and colorless. Oral capsule formulations should be stored per manufacturer instructions, typically at room temperature in a dark, dry location.

Pricing & Available Variants

$50 – $80price range
5mg10mg

Prices sourced from peptides.gg marketplace. Prices may vary.

References

  1. Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008.
  2. Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008.
  3. Brzoska T, Luger TA, Maaser C, et al. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev. 2008.
  4. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration. 2026.
  5. Getting SJ, Schiöth HB, Perretti M. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. J Pharmacol Exp Ther. 2003.
  6. Land SC. Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists. Int J Physiol Pathophysiol Pharmacol. 2012.
  7. Elliott RJ, Szabo M, Wagner MJ, et al. alpha-Melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells. J Invest Dermatol. 2004.
  8. Moustafa M, Szabo M, Ghanem GE, et al. Inhibition of tumor necrosis factor-alpha stimulated NFkappaB/p65 in human keratinocytes by alpha-melanocyte stimulating hormone and adrenocorticotropic hormone peptides. J Invest Dermatol. 2002.
  9. Catania A, Garofalo L, Cutuli M, et al. Melanocortin peptides inhibit production of proinflammatory cytokines in blood of HIV-infected patients. Peptides. 1998.
  10. Delgado R, Carlin A, Airaghi L, et al. Melanocortin peptides inhibit production of proinflammatory cytokines and nitric oxide by activated microglia. J Leukoc Biol. 1998.
  11. Sun J, Xue P, Liu J, et al. Self-Cross-Linked Hydrogel of Cysteamine-Grafted γ-Polyglutamic Acid Stabilized Tripeptide KPV for Alleviating TNBS-Induced Ulcerative Colitis in Rats. ACS Biomater Sci Eng. 2021.
  12. Cutuli M, Cristiani S, Lipton JM, et al. Antimicrobial effects of alpha-MSH peptides. J Leukoc Biol. 2000.
  13. Rauch I, Holzmeister S, Kofler B. Anti-Candida activity of alpha-melanocyte-stimulating hormone (alpha-MSH) peptides. J Leukoc Biol. 2009.
  14. Böhm M, Luger T. Are melanocortin peptides future therapeutics for cutaneous wound healing? Exp Dermatol. 2019.

Related Peptides

Track KPV in Your Protocol

Log your KPV doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.

Start Tracking Free